Background Information on Medicare Plans to Help You Make a Choice
In Karen Tellen-Lawton’s column, she gives a little background information on Medicare in effort to help the reader to understand
Read More
Part D/Prescription Drugs
Trump, GOP In Congress Could Use “Must-Pass” Bills To Bring Health Changes
(By Julie Rovner for Kaiser Health News) Throughout the campaign, President-Elect Donald Trump’s entire health message consisted of promising to
Read MoreBig Pharma’s big question: Is Trump friend or foe?
(By Dylan Scott for STAT) WASHINGTON — Should President Donald Trump make drug makers relieved? Or anxious? Continue reading article here… Notice:
Read MoreNovel system to get dying patients an experimental cancer drug raises hopes — and thorny questions
(By Karen Weintraub for STAT) The drug was still experimental, but clinical trials suggested it could be a lifesaver for
Read MoreSupreme Court lets pay-to-delay ruling against pharma stand
(By Ed Silverman for STAT) Cash is not always king. In a move that should settle a highly contentious legal
Read MoreCalifornia’s Drug Price Initiative: Will Voters ‘Send A Signal To Washington’?
(By Pauline Bartolone for California Healthline) This year, Mary O’Connor and her father made voting a family affair. O’Connor’s father
Read MoreThis drug discount program is good for Americans. But pharma wants to gut it
(By Ted Slafsky for STAT) Sticker shock over the cost of drugs isn’t going away any time soon. Drug prices
Read MoreHealth officials find first cases of new superbug in US
(By Sharon Begley for STAT) Just five months after federal health officials asked hospitals and physicians to be on the
Read MoreWhat clinical trial results? Now you can see who isn’t sharing their findings
(By Ed Silverman for STAT) The results for nearly half of all clinical trials conducted by big drug makers during
Read MoreShopping Guide for Medicare Part D Plans
In Philip Moeller’s column “Ask Phil” for PBS Newshour, he reviews the basics of the Medicare Part D benefit and
Read More